Management of Breakthrough Pain Due to Cancer

ONCOLOGY

Volumn 13, Issue 8, 1999, Pages 1103-1108

  Simmonds, Mary A ^a  

^a PENNSYLVANIA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; NARCOTIC ANALGESIC AGENT;

CLASSIFICATION; HUMAN; INTRACTABLE PAIN; NEOPLASM; PAIN; QUALITY OF LIFE; REVIEW;

ANALGESICS, OPIOID; ANTINEOPLASTIC AGENTS; HUMANS; NEOPLASMS; PAIN; PAIN, INTRACTABLE; QUALITY OF LIFE;

EID: 0033173709     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Daut RL, Cleeland CS: The prevalence and severity of pain in cancer. Cancer 50:1913-1918, 1982.
2. Bonica JJ: Cancer pain, in Bonica JJ (ed): The Management of Pain, pp 400-460. Philadelphia, Lea and Febiger, 1990.
3. Zech DF, Grond S, Lynch J, et al: Validation of World Health Organization guidelines for cancer pain relief: A 10-year prospective study. Pain 63:65-76, 1995.
4. Portenoy RK, Hagen NA: Breakthrough pain: Definition, prevalence, and characteristics. Pain 41:273-281, 1990.
5. Mercadante S, Maddaloni S, Roccella S, et al: Predictive factors in advanced cancer pain treated only by analgesics. Pain 50:151-155, 1992.
6. Osborne R, Joel S, Trew D, et al: Morphine and metabolite behavior after different routes of morphine administration: Demonstration of the importance of the active metabolite morphine-6-glucuronide. Clin Pharmacol Ther 47:12-19, 1990.
7. Poyhia R, Seppala T, Olkkola KT, et al: The pharmacokinetics and metabolism of oxycodone after intramuscular and oral administration to healthy subjects. Br J Clin Pharmacol 33:617-621, 1992.
8. Leow KP, Smith MT, Watt JA, et al: Comparative oxycodone pharmacokinetics in humans after intravenous, oral, and rectal administration. Ther Drug Monit 14:419-484, 1992.
9. Leow KP, Smith MT, Watt JA, et al: Single-dose and steady-state pharmacokinetics and pharmacodynamics of oxycodone in patients with cancer. Clin Pharmacol Ther 52:487-495, 1992.
10. Cleeland CS: The impact of pain on the patient with cancer. Cancer 54:2635-2641, 1984.
11. World Health Organization: Cancer Pain Relief and Palliative Care. Geneva, Switzerland, World Health Organization, 1990.
12. Howard OM, Fairclough DL, Daniels ER, et al: Physician desire for euthanasia and assisted suicide: Would physicians practice what they preach? J Clin Oncol 15:428-432, 1997.
13. Burris HA, Moore MJ, Andersen J, et al: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial. J Clin Oncol 15(6):2403-2413, 1997.
14. Tannock IF, Osoba D, Stockier MR, et al: Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: A Canadian randomized trial with palliative endpoints. J Clin Oncol 14:1756-1764, 1996.
15. Cherny NI, Portenoy RK: Practical Issues in the Management of Cancer Pain. New York, Churchill Livingstone, 1994.
16. De Boer AG, De Leede LGJ, Breimer DD: Drug absorption by sublingual and rectal routes. Br J Anaesth 56:69-82, 1984.
17. Pitorak EF, Kraus JC: Pain control with sublingual morphine: The advantages for hospice care. Am J Hospice Care, pp 39-41, March/April 1987.
18. Davis T, Miser AW, Loprinzi CL, et al: Comparative morphine pharmacokinetics following sublingual, intramuscular, and oral administration in patients with cancer. The Hospice Journal 9:85-90, 1993.
19. Weinberg DS, Inturrisi CE, Reidenberg B, et al: Sublingual absorption of selected opioid analgesics. Clin Pharmacol Ther 44:335-337, 1988.
20. McQuay HJ, Moore RA, Bullingham RES: Sublingual morphine, heroin, methadone, and buprenorphine: Kinetics and effects, in Foley KM, Inturrisi CE (eds): Advances in Pain Research and Therapy. vol 8, pp 407-412. New York, Raven Press, 1986.
21. Zhang H, Robinson JR: Routes of drug transport across oral mucosa, in Rathbone MJ (ed): Oral Mucosal Drug Delivery, p 51. New York, Marcel Dekker, 1996.
22. Fine PG, Marcus M, De Boer AJ, et al: An open label study of oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough cancer pain. Pain 45:149-153, 1991.
23. Farrar JT, Cleary J, Rauck R, et al: Oral transmucosal fentanyl citrate: Randomized, double-blinded, placebo-controlled trial for treatment of breakthrough pain in cancer patients. J Natl Cancer Inst 90:611-616, 1998.
24. Streisand JB, Rosenberg JA, Ashburn MA, et al: Oral transmucosal fentanyl citrate: Repeated dose pharmacokinetics. Anesthesiology 79, 1993.
25. Simmonds MA: Oral transmucosal fentanyl citrate produces pain relief faster than medication typically used for breakthrough pain in cancer patients (abstract). Proc Am Soc Clin Oncol 16:52a, 1997.
26. Sevarino FB, Ginsberg B, Lichtor JL, et al: Oral transmucosal fentanyl citrate (OTFC) compared with IV morphine for acute pain in patients following abdominal surgery. Anesth Analg 84:S330, 1997.
27. Christie JM, Simmonds M, Patt R, et al: Dose-titration multicenter study of oral transmucosal fentanyl citrate for the treatment of breakthrough pain in cancer patients using transdermal fentanyl for breakthrough pain. J Clin Oncol 16:3238-3245, 1998.
28. de Stoutz ND, Bruera E, Suarez-Almazor M: Opioid rotation for toxicity reduction in terminal cancer patients. J Pain Symptom Manage 10:378-384, 1995.
29. Bruera E, Roca E, Cedaro L, et al: Action of oral methylprednisolone in terminal cancer patients: A prospective randomized double-blind study. Cancer Treat Rep 69:751-754, 1985.
30. Citron ML, Kalra JM, Seltzer VL, et al: Patient-controlled analgesia for cancer pain: A long-term study of inpatient and outpatient use. Cancer Invest 10:335-341, 1992.
31. Baumann TJ, Batenhorst RL, Graves DA, et al: Patient-controlled analgesia in the terminally ill cancer patient. DICP Ann Pharmacother 20:297-301, 1986.
32. Citron ML, Johnston-Early A, Boyer M, et al: Patient-controlled analgesia for severe cancer pain. Arch Intern Med 146:734-736, 1986.
33. Portenoy RK: Issues in the economic analysis of therapies for cancer pain. Oncology 9(suppl):71-78, 1995.
34. Callan CM: An analysis of complaints and complications with patient-controlled analgesia. in Ferrante FM (ed): Patient-Controlled Analgesia. Oxford, Blackwell Scientific Publications, 1990.